Drugs / rBet v1-FV
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01490411 | Oct 2010 → Apr 2011 | allergic disease | Allergopharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 2 | NCT00841516 | Dec 2007 → Apr 2011 | allergic disease | Allergopharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 2 | NCT00266526 | Jul 2003 → Jul 2004 | ragweed sensitivity | Allergopharma GmbH & Co. KG | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT00554983 | Sep 2007 → Jun 2010 | allergic disease | Allergopharma GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rBet v 1-FV | “OBJECTIVE: To find the optimal dose of a new hypoallergenic folding variant of recombinant Bet v 1 (rBet v 1-FV) as SIT for patients with birch pollen allergy.” PMID 23621350 ↗ Apr 20135“A hypoallergenic recombinant folding variant of the major birch pollen allergen (rBet v 1-FV) was compared with an established native birch preparation.” PMID 26328056 ↗ Aug 2015 “Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, rBet v 1-FV” NCT00554983 ↗ “Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV” NCT00266526 ↗ |
| Modality | Protein / enzyme biologic | “rBet v 1-FV could be administered in higher doses than the native protein with no increase in adverse effects.” PMID 26328056 ↗ Aug 2015 |
| Route | Subcutaneous | “51 patients (24 rBet v 1-FV, 27 native extract) started therapy with subcutaneous allergen immunotherapy (SCIT).” PMID 26328056 ↗ Aug 2015 |